Aquinox Pharmaceuticals, Inc. commenced operations in 2006 as a spin-off from the University of British Columbia, the BC Cancer Agency, and the Vancouver Coastal Health Research Institute, all organizations with outstanding reputations for world-class research.
Aquinox Pharmaceuticals is a clinical-stage pharmaceutical company discovering and developing novel drug candidates to treat inflammation, inflammatory pain, and blood cancers. We are dedicated to advancing novel therapeutics that we believe will make a clinically meaningful difference in patients’ lives.
Our primary focus is anti-inflammatory product candidates targeting SH2-containing inositol-5′-phosphatase 1, or SHIP1, an enzyme that plays a role in an important cellular signaling pathway in immune cells, known as the PI3K pathway. Aquinox has a broad intellectual property portfolio and pipeline of drug candidates that activate SHIP1.
Contact:
Address: Suite 450 – 887 Great Northern Way, Vancouver, BC, Canada, V5T 4T5
Tel.: +1 604 629 9223
Website: http://aqxpharma.com/